Vnitr Lek 2017, 63(4):267-271 | DOI: 10.36290/vnl.2017.054

AT1 blockers - comparability with ACE inhibitors

Václav Monhart1,2
1 Interní klinika 1. LF UK a ÚVN - VFN Praha
2 Ambulance nefrologie, Synlab Czech s.r.o., Praha

The reduction in overall mortality, cardiovascular mortality and the occurrence of myocardial infarction in patients treated with AT1 blockers is comparable with the use of ACE inhibitors. In addition, there is a lower proportion of AT1 blockers withdrawal of treatment due to adverse reactions.

Keywords: ACE inhibitors; AT1 blockers; cardioprotection; hypertension; renin-angiotensin-aldosteron system

Received: April 4, 2017; Accepted: April 21, 2017; Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Monhart V. AT1 blockers - comparability with ACE inhibitors. Vnitr Lek. 2017;63(4):267-271. doi: 10.36290/vnl.2017.054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mielke MM, Rosenberg PB, Tschanz J et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69(19): 1850-1858. Go to original source... Go to PubMed...
    2. Roselli F, Tartaglione B, Federico F et al. Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors. Clin Neurol Neurosurg 2009; 111(4): 327-330. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clineuro.2008.10.006>. Go to original source... Go to PubMed...
    3. Poulter N. ARBs in hypertension. Br J Cardiol 2010; 17(Suppl): s6-s9. Dostupné z WWW: <https://bjcardio.co.uk/2010/05/arbs-in-hypertension/>.
    4. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2014; (8): CD009096. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD009096.pub2>. Go to original source... Go to PubMed...
    5. Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf 2015; 38(1): 33-54. Dostupné z DOI: <http://dx.doi.org/10.1007/s40264-014-0239-7>. Go to original source... Go to PubMed...
    6. Dézsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs 2016; 16(4): 255-266. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256-016-0165-4>. Go to original source... Go to PubMed...
    7. Verdecchia P, Angeli F, Cavallini C et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009; 30(6): 679-688. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn575>. Go to original source... Go to PubMed...
    8. Verdecchia P, Gentile G, Angeli F et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6(2): 81-91. Dostupné z DOI: <http://dx.doi.org/10.1177/1753944712444866>. Go to original source... Go to PubMed...
    9. Bangalore S, Fakheri R, Toklu B et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 2016; 91(1): 51-60. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2015.10.019>. Go to original source... Go to PubMed...
    10. Widimský J, Widimský J, jr. Esenciální a sekundární hypertenze pro praxi. Triton: Praha 2005. ISBN 80-7254-711-9.
    11. Widimský J, Monhart V. Antagonisté receptorů angiotenzinu II. typu AT1 (AT1 blokátory). In: Widimský J et al. Hypertenze. 3. vyd. Triton: Praha 2008: 362-379. ISBN 978-80-7387-077-5.
    12. Widimský J, Monhart V. Antagonisté receptorů angiotenzinu II. typu AT1 (AT1 blokátory). In: Widimský J et al. Antagonisté renin-angiotenzin-aldesteronového systému. Triton: Praha 2011: 113-158. ISBN 978-80-7387-499-5.
    13. Widimský J, Widimský J jr. Farmakoterapie hypertenze. Maxdorf: Praha 2016. ISBN 978-80-7345-477-7.
    14. Van Zwieten PA, Farsang C. Interactions between antihypertensive agents and other drugs. Blood Press 2003;12(5-6):351-352. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.